To improve treatment of gynecologic cancer, efforts have been made to perform comprehensive molecular profiling, both globally, like the TCGA initiative https://cancergenome.nih.gov/, but also by individual research group. The Bergen Gynecologic Cancer research group has contributed several important breakthroughs on molecular profiling of in particular endometrial cancer. In parallel, several potent biomarkers have been identified, by us and others, which could better select patients for more individualized treatment. However, this knowledge has had little effect on current treatment practice. The advances in molecular knowledge need to be followed by functional studies of both effect of specific molecular alterations (mutations, amplification/deletions or translational regulations) and potential link between a specific biomarker and response to drug treatment. Our research group focuses on expanding our knowledge on molecular alterations in gynecologic cancers and aim to perform functional studies to aid clinical implementation of relevant findings.
The group is headed by Professor Camilla Krakstad.
Funding from Forskningsrådet, Kreftforeningen, Helse Vest, UIB and Bergen Research foundation.
The study is part of a collaborative platform with Harvard, Dana Farber Cancer Institute, and MIT working towards the global characterisation of molecular alterations in metastatic gynaecologic cancer.